Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction

The current study was conducted on a sample of 91 patients diagnosed with diastolic dysfunction (DD) with preserved systolic function caused by a painful chronic ischaemic cardiopathy - angina pectoris stable at the effort. The diagnosis was established following anamnesis, electrocardiogram, and ec...

Full description

Saved in:
Bibliographic Details
Published inJournal of enzyme inhibition and medicinal chemistry Vol. 33; no. 1; pp. 1292 - 1298
Main Authors Coculescu, Bogdan Ioan, Dincă, Gabi Valeriu, Bălăeţ, Constantin, Manole, Gheorghe, Bălăeţ, Maria, Stocheci, Cristina Mariana
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.01.2018
Taylor & Francis Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The current study was conducted on a sample of 91 patients diagnosed with diastolic dysfunction (DD) with preserved systolic function caused by a painful chronic ischaemic cardiopathy - angina pectoris stable at the effort. The diagnosis was established following anamnesis, electrocardiogram, and echocardiography. Myeloperoxidase (MPO) serum levels were assessed in all patients and then these values were correlated with some of the echocardiography parameters that proved the mentioned diagnosis. In conclusion, the execution of this investigation triad (electrocardiogram, echocardiography, and MPO) allows: Stratifying the patients depending on the disease risk by early detecting of any possible DD with preserved systolic function. The use of the MPO increased circulating levels as a biomarker for diagnosis and risk due to the statistically significant correlation between those and the results of the other two aforementioned paraclinical investigation.
ISSN:1475-6366
1475-6374
DOI:10.1080/14756366.2018.1499626